Efficacy, Safety and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
media
posted on 2021-01-06, 14:32 authored by Viral N. Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju<p><strong>Article full
text</strong></p>
<p> </p>
<p><br></p>
<p> </p>
<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.</p>
History
Related Materials
- 1.
- 2.
